Effects of Intranasal Naloxone on Hypoglycemia-associated Autonomic Failure in Susceptible Individuals
Authors' conclusion
This is the first study to report that intranasal naloxone, a widely used opioid receptor antagonist, may ameliorate some features of HAAF. Further investigation is warranted into mechanisms of variable interindividual susceptibility to HAAF and the effects of intranasal naloxone in people with diabetes at risk for HAAF.
Study context
- Population
- Healthy nondiabetic volunteers9 developed hypoglycemia-associated autonomic failure (HAAF)
- Participants
- 17 volunteers
- Comparison
- Intranasal naloxone vs placebo
- Primary endpoint
- Differences in counterregulatory hormone responses and hypoglycemia symptoms between first and third hypoglycemic episodes, naloxone vs placebo
Methodological detailsdouble-blinded, placebo-controlled, crossover, academic research center
- Double-blinded
- Placebo-controlled
- Crossover
- Academic research center
Primary result
As reported in the abstract
- Naloxone maintained some hormonal and symptomatic responses to hypoglycemia and prevented the associated requirement for increased glucose infusion
- Naloxone reduced plasma epinephrine and GH responses to the first hypoglycemic episode but prevented further reduction with subsequent hypoglycemia
Further findings
- Participants who developed HAAF
- 9 of 17
- Variable interindividual susceptibility
Original publication
Effects of Intranasal Naloxone on Hypoglycemia-associated Autonomic Failure in Susceptible Individuals. J Clin Endocrinol Metab. Published 19 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →